Alogliptin: A new addition to the class of DPP-4 inhibitors

Diabetes, Metabolic Syndrome and Obesity

Volumn 2, Issue , 2009, Pages 117-126

  Andukuri, Radha ^a   Drincic, Andjela ^a   Rendell, Marc ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alogliptin; DPP 4 inhibitors; GLP 1; Saxagliptin; Sitagliptin; Vildagliptin

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; PIOGLITAZONE; PLACEBO;

ADD ON THERAPY; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; ECZEMA; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PHARMACODYNAMICS; PRURITUS; RASH; REVIEW; RHINOPHARYNGITIS; SKIN TOXICITY; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; WEIGHT CHANGE;

EID: 77953181717     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/dmso.s4312     Document Type: Review

References (87)

1. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88(4):787-835.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053.
3. UK prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
4. Saydah S, Fradkin J, Cowie C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291(3):335-42.
5. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157.
6. Gautier JF, Fetita S, Sobngwi E, Salaün-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab. 2005;31(3 Pt 1):233-42.
7. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3(3):153-165.
8. Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci. 2000;66(2):91-103.
9. Trümper A, Trümper K, Hörsch D. Mechanisms of mitogenic and antiapoptotic signaling by glucose-dependent insulinotropic polypeptide in beta (INS-1) cells. J Endocrinol. 2002;174(2):233-246.
10. Trümper A, Trümper K, Trusheim H, Arnold R, Göke B, Hörsch D. Glucosedependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol. 2001;15(9):1559-1570.
11. Ross SA, Brown JC, Dupré J. Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes. 1977;26(6):525-529.
12. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50(3):609-613.
13. Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes. 2001;50(5):1004-1011.
14. Zhou J, Livak MF, Bernier M, et al. Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets. Am J Physiol Endocrinol Metab. 2007;293(2):E538-547.
15. Pratley R. Islet dysfunction: An underlying defect in the pathophysiology of type 2 diabetes. Endocrinol Metab Clin North Am. 2006; 35 Suppl 1:6-11.
16. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60(4):470-512.
17. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717-3723.
18. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46-52.
19. Vollmer K, Gardiwal H, Menge BA, et al. Hyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humans. J Clin Endocrinol Metab. 2009; 94(4):1379-1385.
20. Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes. 2008;57(3):678-687.
21. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91(1):301-307.
22. Little TJ, Pilichiewicz AN, Russo A, et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab. 2006;91(5):1916-1923.
23. Dupre J. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Regul Pept. 2005;128(2):149-157.
24. Zander M, Christiansen A, Madsbad S, Holst JJ. Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes. Diabetes Care. 2004;27(8):1910-1914.
25. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53(5):1187-1194.
26. Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, Elahi D. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care. 2003;26(10):2835-2841.
27. Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287(6): E1209-1215.
28. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care. 2003;26(8):2370-2377.
29. Moretto T, Milton D, Ridge T, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30(8):1448-1460.
30. Zinman B, Hoogwerf B, Durán García S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146(7):477-485.
31. DeFronzo R, Ratner R, Han J, Kim D, Fineman M, Baron A. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092-1100.
32. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628-2635.
33. Dupré J, Behme MT, McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab. 2004;89(7):3469-3473.
34. Ahrén B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res. 2004;36(11-12): 867-876.
35. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia. 2005;48(4):616-620.
36. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194-206.
37. Lyseng-Williamson KA. Sitagliptin. Drugs. 2007;67(4):587-597.
38. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H; Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2564-2571.
39. Zerilli T, Pyon EY. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clin Ther. 2007;29(12):2614-2634.
40. Williams-Herman D, Johnson J, Teng R. et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin. 2009;25(3):569-583.
41. Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008;24(2):537-550.
42. Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(10):959-969.
43. Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin. 2008;24(2):489-496.
44. Croxtall JD, Keam SJ. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2008;68(16):2387-2409.
45. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drugnaïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007;39(3):218-223.
46. Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009 Mar 23. [Epub ahead of print].
47. Göke B, Hershon K, Kerr D, et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Horm Metab Res. 2008;40(12):892-895.
48. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11(2):157-166.
49. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24(10):2943-2952.
50. Madsbad S, Krarup T, Deacon CF, Holst JJ. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care. 2008;11(4):491-499.
51. Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007;50:2297-2300.
52. Christopher R, Davenport M, Gwaltney S, et al. Pharmacokinetic and pharmacodynamic profiles of SYR-322, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys [abstract]. Diabetes. 2006; 55 Suppl 1:A107-A108.
53. Karim A, Bridson W, Fleck P, et al. Disposition of the dipeptidyl peptidase-4 inhibitor[14C] alogliptin benzoate ([14C]SYR-322) after oral administration to healthy male subjects [abstract]. AAPS J. 2007;9(S2):T3552.
54. Covington P, Christopher R, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008;30(3):513-527.
55. Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double- blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008;30(3):499-512.
56. Covington P,Christopher R,Davenport M, et al. Lack of pharmacokinetic interaction between alogliptin benzoate (SYR-322) and metformin in healthy subjects [abstract]. Diabetes. 2007;56(suppl 1): A541-A542.
57. Fleck P, Karim A, Harris S, et al. Lack of effect of multiple doses of alogliptin benzoate (SYR-322) on the pharmacokinetics of glyburide in healthy subjects [abstract]. Diabetes. 2007;56(suppl 1):A?
58. Karim A, Fleck P, Joseph M, et al. No pharmacokinetic interaction between alogliptin benzoate (SYR-322) and pioglitazone hydrochloride [abstract]. Diabetes. 2007;56 Suppl 1:A536.
59. Karim A, Harris S, Fleck P, Moore Schuster J, Zhang W, Mekki Q. Effect of fluconazole, ketoconazole, and gemfibrozil on the pharmacokinetics of alogliptin benzoate (SYR-322) in healthy subjects [abstract 105]. J Clin Pharmacol. 2007;47(9):1207.
60. Karim A, Harris S, Fleck P, Moore R, Zhang W, Mekki Q. Assessment of drug interaction between alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 inhibitor, and warfarin at steady state [abstract 106]. J Clin Pharmacol. 2007;47(9):1207.
61. Karim A, Chiselko P, Fleck P, Harris S, Munsaka M, Mekki Q. Lack of effect of cyclosporine on the single dose pharmacokinetics of alogliptin, a novel dipeptidyl peptidase-4 inhibitor, in healthy male subjects [abstract]. Clin Pharmacol Ther. 2008;83 Suppl 1:S13.
62. Karim A, Copa A, Fleck P, Helland J, Munsaka M, Mekki Q. Effects of alogliptin on the pharmacokinetics and pharmacodynamics of norethindrone and ethinyl estradiol (ORTHO- NOVUM(R) 1/35) in healthy adult female subjects [abstract]. Clin Pharmacol Ther. 2008;83 Suppl:S13.
63. Karim A, Fleck P, Harris S, Munsaka M, Weiss M, Mekki Q. Lack of pharmacokinetic interaction between alogliptin, a highly selective dipeptidyl peptidase-4 inhibitor, and atorvastatin in healthy subjects [abstract]. Clin Pharmacol Ther. 2008;83 Suppl 1:S14.
64. Karim A, Fleck P, Harris S, Weiss M, Zhang W, Mekki Q. Lack of pharmacokinetic interaction between multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin and digoxin in healthy subjects [abstract]. Clin Pharmacol Ther. 2008;83 Suppl 1:S12-S13.
65. Defronzo R, Fleck P, Wilson C, Mekki Q; Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31:2315-2317.
66. Pratley R, Kipnes M, Fleck P, Wilson C, Mekki Q; Alogliptin Study 007 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab. 2009;11(2):167-176.
67. Nauck M, Ellis G, Fleck P, Wilson C, Mekki Q; Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009;63(1):46-55.
68. Pratley R, Reusch J, Fleck P, Wilson C, Mekki Q. Alogliptin added to pioglitazone therapy improves glycemic control in patients with type 2 diabetes without increasing weight gain or hypoglycemia [abstract]. Diabetologia. 2008;51 Suppl 1:S343.
69. Rendell M, Rosenstock J, Gross J, Fleck P, Wilson C, Mekki Q. Addition of Alogliptin to insulin therapy reduces HbA1c without increasing weight gain or hypoglycemia in patients with type 2 diabetes [abstract]. Diabetologia. 2008;51 Suppl 1:S37.
70. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag. 2008;4(4):753-768.
71. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(5):376-386.
72. Defronzo RA, Hissa MN, Garber AJ, et al; for the Saxagliptin 014 Study Group. The Efficacy and safety of Saxagliptin when added to Metformin therapy in patients with inadequately controlled Type 2 diabetes on Metformin alone. Diabetes Care. 2009 Jun 23. [Epub ahead of print].
73. Emea.europa.edu [homepage on the internet]. Summary of product characteristics of vildagliptin. http://www.emea.europa.eu/humandocs/ PDFs/ EPAR/galvus/H-771-PI-en.pdf. Accessed June 26, 2009.
74. Merck shares Januvia safety data following FDA decision to delay approval of rival drug. Internal medicine world report; issue December 2006. http://www.imwr.com/issues/articles/2006-12-45.asp. Accessed June 26, 2009.
75. Emea.europa.edu [homepage on the internet]. Scientific discussion on vildagliptin: pharmacodynamics, pharmacokinetics, efficacy and safety. www.emea.europa.eu/humandocs/PDFs/EPAR/eucreas/H-807-en6.pdf. Accessed June 26, 2009.
76. Fda.gov/medwatch[homepage on the internet]. Patient information Januvia; Oct 2007. www.fda.gov/medwatch/safety/2007/Oct-PI/ Januvia-PI.pdf. Accessed June 26, 2009.
77. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696- 1705.
78. Lambeir AM, Scharpé S, De Meester I. DPP4 inhibitors for diabetes - what next? Biochem Pharmacol. 2008;76(12):1637-1643.
79. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007;30(2):217-223.
80. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab. 2008;10(1): 82-90.
81. Reinhold D, Goihl A, Wrenger S et al. Role of dipeptidyl peptidase IV (DPP IV)-like enzymes in T lymphocyte activation: investigations in DPP IV/CD26-knockout mice.Clin Chem Lab Med. 2009 Feb 10. [Epub ahead of print].
82. Burkey BF, Hoffmann PK, Hassiepen U, Trappe J, Juedes M, Foley JE. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab. 2008;10(11):1057-1061.
83. Karim A, fleck P, Hetman L, Marbury T, Ravis W, Cannon C, et al. Single dose pharmacokinetics of dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment [poster 538 P]. Diabetes. 2008;57 Suppl 1:A160.
84. Karim A, fleck P, Dorsey D, Zhang W, Mekki Q, Preston RA. Single dose pharmacokinetics of alogliptin benzoate(SYR-322) in subjects with moderate hepatic impairment [abstract 107]. J Clin Pharmacol. 2007;47(9):1207.
85. Nathan DM. Finding new treatments for diabetes - how many, how fast... how good? N Engl J Med. 2007;356(5):437-440.
86. Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40(3):209-294.
87. Chia CW Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2008;93(10):3703-3716.